Keros Therapeutics, Inc. (KROS)Healthcare | Biotechnology | Lexington, United States | NasdaqGM
10.83 USD
-0.27
(-2.432%) ⇩
(July 14, 2026, 10:31 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:24 a.m. EDT
The investment case here is fundamentally broken. The company is hemorrhaging cash with negative free cash flow and operating margins of -70%, while revenue has collapsed by nearly 99% year-over-year. The balance sheet, though currently showing a high current ratio, is propped up by minimal debt relative to massive cash reserves that are being burned rapidly; this is a classic 'cash burn' trap where the runway is finite without a proven product launch. The price action confirms this deterioration, having lost over 55% of its value over the last five years, including a catastrophic 68% drop in the most recent fiscal year. While the short-term chart shows a slight bounce off the lows, the underlying business metrics—negative earnings, shrinking sales, and no dividend support—make this a severe avoid. The options market agrees, with traders stacking protection rather than betting on a rally. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.059541 |
| AutoETS | 0.075396 |
| AutoARIMA | 0.078344 |
| MSTL | 0.079490 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 0.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.416 |
| Excess Kurtosis | -0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.711 |
| Revenue per Share | 1.037 |
| Market Cap | 214,345,584 |
| Forward P/E | -1.94 |
| Beta | 0.97 |
| Profit Margins | -256.60% |
| Website | https://www.kerostx.com |
As of July 11, 2026, 5:24 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes below the current price ($10.00 and $12.50), while call activity remains sparse and focused on out-of-the-money strikes. This imbalance suggests a market expectation of further downside or a lack of conviction in a near-term recovery, despite some minor call flow at lower strikes.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22105265 |
| Address1 | 1,050 Waltham Street |
| Address2 | Suite 302 |
| All Time High | 88.8 |
| All Time Low | 9.12 |
| Ask | 13.78 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 291,860 |
| Average Daily Volume3 Month | 312,447 |
| Average Volume | 312,447 |
| Average Volume10Days | 291,860 |
| Beta | 0.97 |
| Bid | 7.85 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 14.475 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.83 |
| Current Ratio | 22.615 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 11.12 |
| Day Low | 10.74 |
| Debt To Equity | 5.711 |
| Display Name | Keros Therapeutics |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -105,780,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.43 |
| Enterprise To Revenue | -1.371 |
| Enterprise Value | -45,496,608 |
| Eps Current Year | -5.186 |
| Eps Forward | -5.59333 |
| Eps Trailing Twelve Months | -2.53 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.9852 |
| Fifty Day Average Change | -0.1552 |
| Fifty Day Average Change Percent | -0.0141281 |
| Fifty Two Week Change Percent | -22.105265 |
| Fifty Two Week High | 22.55 |
| Fifty Two Week High Change | -11.719999 |
| Fifty Two Week High Change Percent | -0.5197339 |
| Fifty Two Week Low | 9.69 |
| Fifty Two Week Low Change | 1.1400003 |
| Fifty Two Week Low Change Percent | 0.1176471 |
| Fifty Two Week Range | 9.69 - 22.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,586,352,600,000 |
| Float Shares | 17,798,403 |
| Forward Eps | -5.59333 |
| Forward P E | -1.9362348 |
| Free Cashflow | -37,688,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.84886 |
| Gross Profits | -61,349,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03709 |
| Held Percent Institutions | 0.95706004 |
| Implied Shares Outstanding | 19,791,837 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. |
| Long Name | Keros Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 214,345,584 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_333195513 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -85,145,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 219,689,390 |
| Number Of Analyst Opinions | 6 |
| Open | 11.12 |
| Operating Cashflow | -57,195,000 |
| Operating Margins | -70.509544 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 314 6297 |
| Previous Close | 11.1 |
| Price Eps Current Year | -2.0883148 |
| Price Hint | 2 |
| Price To Book | 0.7481865 |
| Price To Sales Trailing12 Months | 6.4596944 |
| Profit Margins | -2.566 |
| Quick Ratio | 22.174 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.27000046 |
| Regular Market Change Percent | -2.4324365 |
| Regular Market Day High | 11.12 |
| Regular Market Day Low | 10.74 |
| Regular Market Day Range | 10.74 - 11.12 |
| Regular Market Open | 11.12 |
| Regular Market Previous Close | 11.1 |
| Regular Market Price | 10.83 |
| Regular Market Time | 1,784,039,505 |
| Regular Market Volume | 26,205 |
| Return On Assets | -0.12234 |
| Return On Equity | -0.16785999 |
| Revenue Growth | -0.998 |
| Revenue Per Share | 1.037 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 19,791,837 |
| Shares Percent Shares Out | 0.0519 |
| Shares Short | 1,026,323 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,508,786 |
| Short Name | Keros Therapeutics, Inc. |
| Short Percent Of Float | 0.059699997 |
| Short Ratio | 3.35 |
| Source Interval | 15 |
| State | MA |
| Symbol | KROS |
| Target High Price | 30.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 21.83333 |
| Target Median Price | 20.0 |
| Total Cash | 281,496,992 |
| Total Cash Per Share | 14.223 |
| Total Debt | 16,311,000 |
| Total Revenue | 33,182,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.631175 |
| Two Hundred Day Average Change | -3.801175 |
| Two Hundred Day Average Change Percent | -0.25979972 |
| Type Disp | Equity |
| Volume | 26,205 |
| Website | https://www.kerostx.com |
| Zip | 2,421 |